Objective: To survey the associations between several risk factors and birth defects, in order to detect potential new teratogens. Methods: Data of the two Dutch European Registration of Congenital Anomalies (EUROCAT) registries collected before January 1, 1998 were used to perform χ2 tests for a large number of risk factors and birth defects. Defects caused by chromosomal or monogenic disorders were analyzed separately. Results: Cross-tabulations of 80 groups of birth defects with 303 risk factors were studied. Of these, 126 combinations had a p value under 0.05, and 34 had a p value under 0.001. Of these 34 associations, some are known in the literature, some were found before in the same databases and some were new associations. Conclusions: This is a good method for generating new hypotheses for associations between risk factors and birth defects. It can be a start for new, more in-depth studies of potential teratogens.

Keywords:
Monitoring, Birth defects, Registries, Risk factor, Surveillance, Drugs, Pregnancy
1.
Ten Kate LP, Cornel MC, De Walle HEK: Monitoring of risk factor/outcome combinations: A valuable supplement to birth defect monitoring. Int J Risk Saf Med 1992;3:129–136.
2.
Cornel MC, Erickson JD, Khoury MJ, James LM, Liu Y: Population-based birth-defect and risk-factor surveillance: Data from the Northern Netherlands. Int J Risk Saf Med 1996;8:197–209.
3.
EUROCAT Working group. Epidemiologic surveillance of congenital anomalies: The EUROCAT project. Acta Paediatr 1988;41(suppl 3):641–658.
4.
Lechat MF, Dolk H: Registries of congenital anomalies: EUROCAT. Environ Health Perspect 1993;101(suppl 2):153–157.
5.
Rengelink-van der Lee JH, Zandwijken GRJ, Van Duijn CM: Evaluatie van gegevensverstrekking door apothekers aan EUROCAT. Pharm Weekbl 1996;131:440–443.
6.
The British Paediatric Association: British Paediatric Association Classification of Disease. London, British Paediatric Association, 1979.
7.
EUROCAT Central Registry: EUROCAT Guide 1.1: Instructions for the Registration of Congenital Anomalies. Brussels, Department of Epidemiology, Catholic University of Louvain, 1990.
8.
Miettinen OS: Proportion of disease caused or prevented by a given exposure, trait or intervention. Am J Epidemiol 1974;99:325–332.
9.
Van den Anker JN, Van Vught EE, Zandwijken GR, Cohen-Overbeek TE, Lindhout D: Severe limb abnormalities: analysis of a cluster of five cases born during a period of 45 days. Am J Med Genet 1993;45:659–667.
10.
De Walle HE, Van der Pal KM, De Jong-van den Berg LT, Jeeninga W, Schouten JS, De Rover CM et al: Effect of mass media campaign to reduce socioeconomic differences in women’s awareness and behaviour concerning use of folic acid: cross sectional study. BMJ 1999;319:291–292.
11.
Reefhuis J, De Walle HE, Cornel MC: Maternal smoking and deformities of the foot: Results of the EUROCAT Study. European Registries of Congenital Anomalies (letter). Am J Public Health 1998;88:1554–1555.
12.
Gaulden ME: Maternal age effect: The enigma of Down syndrome and other trisomic conditions. Mutat Res 1992;296:69–88.
13.
Griffin DK: The incidence, origin, and etiology of aneuploidy. Int Rev Cytol 1996;167:263–296.
14.
Lammer EJ, Sever LE, Oakley GP Jr: Teratogen update: Valproic acid. Teratology 1987;35:465–473.
15.
Nau H: Valproic acid-induced neural tube defects. Ciba Found Symp 1994;181:144–152.
16.
Byron-Scott R, Haan E, Chan A, Bower C, Scott H, Clark K: A population-based study of abdominal wall defects in South Australia and Western Australia. Paediatr Perinat Epidemiol 1998;12:136–151.
17.
Lubinsky MS: Association of prenatal vascular disruptions with decreased maternal age. Am J Med Genet 1997;69:237–239.
18.
Lewis DP, Van Dyke DC, Stumbo PJ, Berg MJ: Drug and environmental factors associated with adverse pregnancy outcomes. I. Antiepileptic drugs, contraceptives, smoking, and folate. Ann Pharmacother 1998;32:802–817.
19.
Martinez-Frias ML: Epidemiological analysis of outcomes of pregnancy in diabetic mothers: Identification of the most characteristic and most frequent congenital anomalies. Am J Med Genet 1994;51:108–113.
20.
Mills JL: Malformations in infants of diabetic mothers. Teratology 1982;25:385–394.
21.
Robert E, Vollset SE, Botto L, Lancaster PAL, Merlob P, Mastroiacovo P, Cocchi G, Ashizawa M, Sakamoto S, Orioli I: Malformation surveillance and maternal drug exposure: the MADRE project. Int J Risk Saf Med 1994;6:75–118.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.